Today: 27 June 2026

Leokadia Głogulska

Leokadia Głogulska is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, space technology and global market developments. She graduated from Wrocław University of Economics and Business and previously worked in financial analysis before moving into business journalism. Her reporting focuses on helping readers understand the market trends, companies and technologies shaping the global economy.

SoFi stock rises premarket after CEO Anthony Noto buys shares again

SoFi stock rises premarket after CEO Anthony Noto buys shares again

SoFi shares jumped 3.44% pre-market to $18.02 after CEO Anthony Noto disclosed buying 13,888 shares, boosting his stake to nearly 12 million, following a weak close and hawkish Fed signals; the insider purchase stands out as a key catalyst for the stock ahead of a shortened trading week, as investors weigh rate risks and mixed business segment performance.
18 June 2026
·
Coherent shares drop after $50 million CHIPS grant raises questions for AI optics

Coherent shares drop after $50 million CHIPS grant raises questions for AI optics

Coherent shares slid 1% to $378.85 despite a $50 million U.S. funding pledge for its Texas indium phosphide plant, as investors weighed steep valuation—48.27 times forward earnings—against supply risks and doubts over how quickly AI optics demand will drive profits, even with deepening Nvidia ties and surging wafer prices.
17 June 2026
····
Lloyds shares rise as UK bank rally offsets rate-margin worries

Lloyds shares rise as UK bank rally offsets rate-margin worries

Why did Lloyds Banking Group shares rise after the London close? What was Lloyds' share price and percentage gain at the close? How did UK inflation in May affect Lloyds and other UK banks? What is the significance of the upcoming Bank of England rate decision for Lloyds? How much of Lloyds' loan book is made up of mortgages? What were Lloyds' first-quarter net income and profit growth figures? When will Lloyds report half-year results?
17 June 2026
····
Huntsman Stock Slides After Olin Merger Deal Values HUN Below Prior Close

Huntsman Stock Slides After Olin Merger Deal Values HUN Below Prior Close

Huntsman shares plunged 18% to $13.06 after Olin agreed to acquire the company in an all-stock merger, with the fixed exchange ratio tying Huntsman’s value to Olin’s falling share price; the deal values Huntsman at $13.85 per share based on Olin’s prior close, about 12.8% below Huntsman’s last market close, and the next catalyst is the SEC merger filing and shareholder votes.
16 June 2026
··
CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed soared over 30% premarket after an SEC filing revealed a trust linked to board chair Joshua S. Boger bought $3 million in units above Monday’s close, signaling insider confidence following last week’s $10.5 million private placement that extends cash runway but raises dilution risks; the next key catalyst is securing a strategic partner for neflamapimod’s Phase 3 dementia with Lewy bodies program.
16 June 2026
··
Shell Drops After Oil Slides and Buyback Halt Hits Sentiment

Shell Drops After Oil Slides and Buyback Halt Hits Sentiment

Shell shares slid 0.32% to 3,071p in London, extending Monday’s 4.35% drop, as Brent crude hit a three-month low and investors reacted to Shell’s paused $3 billion buyback amid its pending ARC Resources deal; the buyback pause removes a near-term support for the stock, while falling oil prices threaten cash flow and shareholder returns.
16 June 2026
·
1 … 3 4 5 6 7 … 15

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Go toTop